EmailFacebookLinkedInTwitterGoogle+
Oxford Biotheraputics
News Archives
News Archives

Oxford BioTherapeutics provides regular updates of our R&D, scientific and corporate progress through regular conference presentations, scientific journal publications and press releases. For more information please contact us directly.

09/12/2009

Oxford BioTherapeutics Appoints Michael Moore as Chairman

11/11/2009

Oxford BioTherapeutics Recruits mAb Industry Leaders to Head US Operations

01/12/2008

Oxford Genome Sciences Changes its Name to Oxford BioTherapeutics

18/02/2008

Oxford Genome Sciences Appoints Professor Elke Jaeger to its Scientific Advisory Board

17/12/2007

Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer

21/11/2007

Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors

11/10/2007

Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board

18/09/2007

Oxford Genome Sciences Announces New Therapeutic Antibody Deal with Medarex

18/04/2007

Oxford Genome Sciences Recruits Senior Industry Professionals to Drive its Development of Novel Personalised Medicines

05/03/2007

Oxford Genome Sciences Expands its Scientific Advisory Board

05/02/2007

Oxford Genome Sciences (UK) Ltd secured additional private equity investment round

10/05/2006

Oxford Genome Sciences and Medarex Sign Therapeutic Antibody Collaboration Agreement in Cancer

12/04/2006

Oxford Genome Sciences and University of Oxford to develop new clinical biomarkers for colorectal cancer

05/04/2006

Biosite and Oxford Genome Sciences Announce Collaboration in Colorectal Cancer

07/06/2005

Oxford Genome Sciences appoints Jeff Warren to the Board of Directors

04/04/2005

Oxford Genome Sciences closes financing and moves to state-of-the-art proteomics facility

14/03/2005

Bayer HealthCare Diagnostics and Oxford Genome Sciences Partner in Proteomics-based Evaluation of New Biomarkers for Breast Cancer